Edgestream Partners L.P. Sells 36,972 Shares of Envista Holdings Co. (NYSE:NVST)

Edgestream Partners L.P. cut its stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 24.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 114,953 shares of the company's stock after selling 36,972 shares during the quarter. Edgestream Partners L.P. owned approximately 0.07% of Envista worth $2,217,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Pacer Advisors Inc. raised its holdings in shares of Envista by 22.2% during the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company's stock valued at $69,749,000 after purchasing an additional 642,401 shares during the period. Diamond Hill Capital Management Inc. increased its position in Envista by 8.1% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company's stock valued at $26,394,000 after buying an additional 100,360 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista during the 4th quarter worth approximately $53,000. Lecap Asset Management Ltd. acquired a new position in Envista during the 4th quarter worth approximately $281,000. Finally, Hotchkis & Wiley Capital Management LLC bought a new position in Envista in the third quarter worth approximately $14,965,000.

Envista Stock Down 3.2 %

NYSE:NVST traded down $0.53 on Thursday, hitting $16.21. The stock had a trading volume of 2,777,875 shares, compared to its average volume of 2,288,747. Envista Holdings Co. has a 1 year low of $15.15 and a 1 year high of $23.00. The firm's fifty day simple moving average is $20.10 and its two-hundred day simple moving average is $19.67. The stock has a market cap of $2.79 billion, a P/E ratio of -2.50, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Remove Ads

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Analysts predict that Envista Holdings Co. will post 1 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on NVST. Piper Sandler boosted their price objective on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Mizuho assumed coverage on shares of Envista in a research note on Wednesday, December 4th. They set an "underperform" rating and a $20.00 price target for the company. Jefferies Financial Group raised their price objective on shares of Envista from $20.00 to $22.00 and gave the company a "hold" rating in a research note on Thursday, January 23rd. UBS Group reduced their price objective on shares of Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Monday. Finally, New Street Research set a $19.00 target price on shares of Envista in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Envista currently has an average rating of "Hold" and a consensus target price of $20.18.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.